Digital newsroom

$10 MILLION GRANT FROM EXACT SCIENCES TO SUPPORT STAND UP TO CANCER INITIATIVE TO IMPROVE COLORECTAL CANCER SCREENING AND PREVENTION

New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

Exact Sciences Mourns the Death of Dr. David Ahlquist, a Pioneer in Early Cancer Detection

Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45

Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods

EXACT SCIENCES HIGHLIGHTS THE OPPORTUNITY TO SEEK SCREENING WITH COLOGUARD® THROUGH TELEHEALTH

Message from Chairman & CEO, Kevin Conroy

1 2 3 4 5 6 7 8 9